Literature DB >> 3654924

Absence of the plasma growth hormone-binding protein in Laron-type dwarfism.

G Baumann1, M A Shaw, R J Winter.   

Abstract

We recently described a specific, high affinity binding protein (BP) for growth hormone (GH) in normal human plasma. Little is known about the source, regulation and biological role of this BP. Because its specificity is similar to that of the GH receptor, we considered the possibility that it represented a circulating receptor subunit or fragment. Laron-type dwarfism is a rare disorder characterized by severe growth failure, resistance to GH, and GH receptor deficiency. To probe the relationship between the receptor and the circulating binding protein, we measured the binding of GH to plasma from a child with Laron-type dwarfism and compared it with that in plasma of normal children and adults. Normal plasma samples were supplemented with unlabeled GH to the endogenous GH level in the plasma of the Laron patient to yield comparable saturation of the BP. After incubation of plasma with radiolabeled GH, bound GH was separated from free GH by gel filtration on Sephadex G-100. There was no detectable binding (less than 1.5%) of GH in the plasma of the Laron-type dwarf, whereas in normal children the bound GH fraction averaged 24.0 +/- 6.1% (mean +/- SD). Thus, the GH-BP is either absent or functionally abnormal in Laron-type dwarfism. This finding suggests that the circulating GH-BP is related to and/or may be derived from the GH receptor. Alternatively, it is possible that the BP plays an as yet poorly understood pivotal role in the promotion of somatic growth.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3654924     DOI: 10.1210/jcem-65-4-814

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  A homozygous nonsense mutation of the human growth hormone receptor gene in a Sardinian boy with Laron-type dwarfism.

Authors:  M Putzolu; A Meloni; S Loche; C Pischedda; A Cao; P Moi
Journal:  J Endocrinol Invest       Date:  1997-05       Impact factor: 4.256

2.  Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism.

Authors:  P J Godowski; D W Leung; L R Meacham; J P Galgani; R Hellmiss; R Keret; P S Rotwein; J S Parks; Z Laron; W I Wood
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

Review 3.  Growth hormone, 1988.

Authors:  M O Thorner; M L Vance
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

4.  A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse).

Authors:  Y Zhou; B C Xu; H G Maheshwari; L He; M Reed; M Lozykowski; S Okada; L Cataldo; K Coschigamo; T E Wagner; G Baumann; J J Kopchick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 5.  Circulating growth hormone binding proteins.

Authors:  G Baumann; M A Shaw; K Amburn
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

6.  Radiographic abnormalities in Laron dwarfism.

Authors:  M Vasil; A Baxova; K Kozlowski
Journal:  Pediatr Radiol       Date:  1994

7.  Serum growth hormone-binding protein is decreased in prepubertal children with idiopathic short stature.

Authors:  N Dávila; M Moreira-Andrés; J Alcañiz; B Barceló
Journal:  J Endocrinol Invest       Date:  1996-06       Impact factor: 4.256

8.  Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications.

Authors:  J D Veldhuis; M L Johnson; L M Faunt; M Mercado; G Baumann
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

9.  Lack of hormone binding in COS-7 cells expressing a mutated growth hormone receptor found in Laron dwarfism.

Authors:  M Edery; M Rozakis-Adcock; L Goujon; J Finidori; C Lévi-Meyrueis; J Paly; J Djiane; M C Postel-Vinay; P A Kelly
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

10.  An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation.

Authors:  T W Flickinger; N J Maihle; H J Kung
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.